Ochre Bio
Last verified 2026-06-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $75.0Mattributed |
|---|---|
| Latest round | strategic, $35.0M, 2024-04-22attributed |
| Founded | 2019 |
| Headquarters | Oxford, UK |
| Industry | biotech |
| Stage | series-b+ |
| Website | ochre-bio.com |
Ochre Bio develops RNA therapies for chronic liver disease, pairing proprietary human liver datasets with validation in perfused human livers and tissue. It works toward treatments for patients with advanced fibrosis and cirrhosis. Testing targets in actual human livers, backed by GSK and Boehringer Ingelheim deals.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-22 | strategic | $35.0M | entrepreneur-first |
Detected tech stack
doubleclick floodlight, elementor, fastly, font awesome, google analytics, google tag manager, imagesloaded, jquery, jquery migrate, mariadb, mysql, nginx
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $35.0M | attributed | accelerator named as publisher. No document URL on file. |
| Total raised $75.0M | attributed | accelerator named as publisher. No document URL on file. |
| Company existence | sourced | Y Combinator named as publisher. Document, retrieved 2026-09-17. |
| Description | self-reported | ochre-bio.com, read 2026-06-07 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-24Existence: self-reported → sourced, Y Combinator, document, retrieved 2026-09-17 | Existence | self-reported → sourced | Y Combinator, document, retrieved 2026-09-17 |
Records begin 2026-09-24. All changes